Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

PaperCitations, authors & open-access status

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,250 citations, 2019 year and green oa status.

1,250
Citations
2019
Year
green
OA Status

Related on ScholarIQ

Myung‐Ju Ahn
Author
Yuichiro� Doki
Author
The Lancet Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
Cancer Immunotherapy and Biomarkers
Topic
Esophageal Cancer Research and Treatment
Topic
470M+ articles · free account